Drug Profile


Alternative Names: PX-866

Latest Information Update: 21 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Burnham Institute; University of Arizona; University of Pittsburgh
  • Developer Oncothyreon
  • Class Antineoplastics; Gonanes; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Glioblastoma; Head and neck cancer; Idiopathic pulmonary fibrosis; Malignant melanoma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Feb 2015 Oncothyreon and NCIC Clinical Trials Group, Canada completes a phase II trial in Glioblastoma (Recurrent, Second-line therapy or greater) in Canada (NCT01259869)
  • 13 Mar 2014 Oncothyreon completes phase I portion of a phase I/II trial in Malignant melanoma (combination therapy) in USA (NCT01616199)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top